For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| AMD 3100 (Mozobil Plerixafor ) Volunteers | Peripheral blood hematopoietic progenitor cell mobilization with AMD 3100 (Mozobil plerixafor) in healthy volunteers | None | None | 0 | 8 | 8 | 8 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| elevated Monos (expected) | NON_SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| elevated WBCs (expected) | NON_SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| auditory (R ear) pain | NON_SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| Cramps, abdominal | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| feel need to vomit, no nausea | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Headache | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Hot feeling | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Swelling, leg | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Injection site (erythema) | NON_SYSTEMATIC_ASSESSMENT | Immune system disorders | None | View |
| Injection site (induration) | NON_SYSTEMATIC_ASSESSMENT | Immune system disorders | None | View |
| Injection site (pain) | NON_SYSTEMATIC_ASSESSMENT | Immune system disorders | None | View |
| Injection site (pruritus) | NON_SYSTEMATIC_ASSESSMENT | Immune system disorders | None | View |
| muscle pain | NON_SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| paresthesia (facial tingling) | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Syncope | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| elevated LDH | NON_SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| elevated Lymphs (efficacy measure) | NON_SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| elevated lymphs (expected) | NON_SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| elevated Polys (expected) | NON_SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Sinus tachycardia (rate 103) | NON_SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |